A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis

Sponsor
AstraZeneca
Study ID
NCT01640054
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients in Asia with rheumatoid arthritis (RA).

Key Dates

Start date
Jul 31, 2012
Status verified
Feb 2014
Primary completion
Jul 31, 2013
Completion
Jul 31, 2013

Study Design

Enrollment
115 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dosing regimen
    Open label Oral treatment 100mg once daily

Primary Outcome Measure

Percentage of Patients Who Had at Least 1 Adverse Event in Any Category [ Time Frame: Entry in extension to study termination (variable duration; maximum 52 weeks) ]

Related Studies